New evidence on graft-versus-host disease prevention in stem cell transplants from unrelated donors

Anti-T-lymphocyte globulin (ATLG) for the prevention of graft-versus-host disease (GvHD) reduces complications and infection-related mortality compared with post-transplant cyclophosphamide (PTCy) in allogeneic hematopoietic stem cell transplantation from unrelated donors.

Although PTCy was associated with fewer cases of acute (Grade II–IV) and chronic GvHD, this did not result in a survival benefit for patients with blood cancer.

These initial results from the GRAPPA study were presented by DKMS as a late-breaking abstract at the European Hematology Association Congress (EHA 2026) in Stockholm. ...